Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
Recruiting · NCT06664996 · Registry updated 2024-10-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2024-10-30 | NCT06664996 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| West China Hospital | 359 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| West China Hospital | Chengdu | China | 47 |